Endologix LLC

Endologix LLC plans to close a manufacturing facility in Milpitas, California, acquired through its PQ Bypass takeover, and will lay off 31 employees in May and June as part of the shutdown. The cuts will primarily affect various manufacturing and quality roles, with most layoffs occurring on May 6 and two smaller rounds in the following weeks. Endologix acquired the site along with the Detour peripheral arterial disease device and exited Chapter 11 as a private company owned by Deerfield Partners. The closure and job reductions come amid broader product and regulatory challenges the company has faced, including prior FDA guidance affecting its AFX2 device and recent leadership changes.

Endologix LLC plans to close a manufacturing facility in Milpitas, California acquired from PQ Bypass and will lay off 31 employees in May and June as part of the closure. The cuts will mainly affect manufacturing and quality roles, with most layoffs occurring on May 6 and two smaller rounds in subsequent weeks. The facility had been added after Endologix exited Chapter 11 under Deerfield Partners and acquired PQ’s Detour peripheral arterial disease device. The move follows ongoing business challenges for Endologix, including prior FDA advisories about its AFX2 grafts and recent leadership changes.

Endologix LLC, a 34-year-old medical technology firm, has announced plans to cut 31 jobs at its Milpitas site. The layoffs are part of a restructuring effort aimed at improving operational efficiency. While the specific reasons for the job cuts were not detailed, the company is likely responding to market pressures and the need to streamline its workforce. The planned layoffs highlight the ongoing challenges faced by companies in the medical technology sector as they adapt to changing industry dynamics.